BDTX BLACK DIAMOND THERAPEUTICS INC Business Restructuring 8-K Filing 2024 - Management Changes Black Diamond Therapeutics announced the termination of its Chief Business Officer and Chief Financial Officer as part of a restructuring plan to focus on its lead program BDTX-1535, which is expected to extend its cash runway into the second quarter of 2026.Get access to all SEC 8-K filings of the BLACK DIAMOND THERAPEUTICS INC